Skip to content

Tirzepatide

Dual GIP/GLP-1 agonist · Metabolic

Analyzed in the USA
Tirzepatide 10 mg — MX-1 Labs
CAS#
2023788-19-2
Formula
C225H348N48O68
M.W.
4,813.45 g/mol
PURITY99% HPLC
RUONot for human or veterinary use
Select size
MX$1,399.00

Ships in 24–72 business hours from CDMX · Free shipping over MX$2,500.00

Tirzepatide 10 mg (LY3298176) is a lyophilized research compound — a 39-amino-acid synthetic peptide with a C20 fatty-acid chain, identity confirmed by FTIR and HPLC and 99.7% purity verified by HPLC. Every lot ships with a traceable COA (BTLabs).

Certificate of Analysis
Lot
WL-TR10-P00519
Expires
2028-06
Chromatographic purity
99.7%
FTIR + HPLC
Confirmed
Content
10.5 mg · 105.1% of label
Analyzed by
BTLabs · 2026-06
Preview COA
Technical specifications
Molecular weight
~4,813 Da
Sequence
39-amino-acid synthetic peptide with C20 fatty acid
Format
Sterile lyophilized
Content
10 mg per vial (105% potency on COA)
Purity
99.7% by HPLC (spec ≥98%) on per-lot COA
Identity
Confirmed by FTIR and HPLC (USP <197A>/<621>)
Storage
Lyophilized; store at −20 °C, protect from light

About Tirzepatide 10 mg

Tirzepatide (LY3298176) is a 39-amino-acid synthetic peptide engineered as a dual agonist at the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. Its identity is confirmed by FTIR and its purity by reverse-phase HPLC, with the individual result reported on each lot's Certificate of Analysis (COA).

The compound's initial characterization was published by Coskun et al. in Molecular Metabolism (2018) [1], and research-program data are recorded in peer-reviewed literature and the public trials registry [2].

MX-1 Labs distributes Tirzepatide 10 mg in Mexico as a scientific research compound with laboratory packaging, an auditable lot number (WL-TR10-P00519) and per-vial analytical documentation. Intended strictly for in-vitro laboratory research; it is not a medicine, supplement or consumer product.

Research applications

Tirzepatide acts simultaneously on two G-protein-coupled receptors widely characterized in endocrinology literature: GIP and GLP-1 [1]. Combined activation of both is associated in preclinical models with effects on satiety, insulin sensitivity and energy expenditure. The peptide structure includes non-canonical amino acids (Aib) and conjugation with a C20 fatty acid to extend the plasma half-life observed in pharmacokinetic studies. The specific experimental application corresponds to the receiving laboratory's design and authorized institutional SOP.

Storage and handling

Sealed vial: keep protected from light, humidity and prolonged air exposure per the lot documentation. Once the experimental solution is prepared, keep under documented refrigeration when the protocol requires it, and record the preparation date, diluent used and workstation conditions. Prepared-solution stability depends on the lot-specific COA, the diluent, aseptic technique and the research protocol. Discard the material at any sign of turbidity, suspended particles or color change.

Scientific references

  1. Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist. Molecular Metabolism 2018; 18:3–14. View source on PubMed →
  2. ClinicalTrials.gov — Registered studies for the clinical development of tirzepatide. View registry →

Frequently asked questions

Is it legal to buy research peptides in Mexico?

Yes. Research peptides are sold legally in Mexico strictly for laboratory research use — not for human or veterinary consumption, diagnosis, or treatment. MX-1 Labs sells for research purposes only; at checkout you confirm compliant use under applicable law (COFEPRIS) and your lab's protocols. Nationwide shipping from CDMX.

Other research peptides